Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Nanjing Legend Files for EU Approval of BCMA CAR-T Therapy

publication date: Apr 30, 2021

Nanjing Legend Biotech filed for EU approval of its BCMA CAR-T candidate in patients with multiple myeloma. In 2017, Legend stunned participants at the US ASCO meeting with the 94% complete remission rate of the CAR-T candidate. Later that year, Janssen Pharma, a division of Johnson and Johnson, paid $350 million upfront to partner the drug. Legend-Janssen is seeking European approval of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed or refractory multiple myeloma, based on 95% overall response and 56% complete response in a Phase Ib/II study. More details....

Stock Symbol:  (NSDQ: LEGN)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital